AR090910A1 - Proceso mejorado para preparar rivaroxaban utilizando intermediarios - Google Patents
Proceso mejorado para preparar rivaroxaban utilizando intermediariosInfo
- Publication number
- AR090910A1 AR090910A1 ARP130101486A AR090910A1 AR 090910 A1 AR090910 A1 AR 090910A1 AR P130101486 A ARP130101486 A AR P130101486A AR 090910 A1 AR090910 A1 AR 090910A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- rivaroxaban
- racemic mixture
- stereochemically isomeric
- isomeric form
- Prior art date
Links
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 title abstract 6
- 229960001148 rivaroxaban Drugs 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 abstract 4
- -1 sulfonyl ester compound Chemical class 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- DEXXSYVEWAYIGZ-LBPRGKRZSA-N 4-[4-[(5s)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl]morpholin-3-one Chemical compound O=C1O[C@@H](CN)CN1C1=CC=C(N2C(COCC2)=O)C=C1 DEXXSYVEWAYIGZ-LBPRGKRZSA-N 0.000 abstract 1
- QZLSBOVWPHXCLT-UHFFFAOYSA-N 5-chlorothiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(Cl)S1 QZLSBOVWPHXCLT-UHFFFAOYSA-N 0.000 abstract 1
- 108010074860 Factor Xa Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
El proceso en un solo recipiente que es industrialmente ventajoso para la preparación de Rivaroxaban o una forma estereoquímicamente isomérica o una mezcla racémica de las mismas, con alto rendimiento y pureza, utilizando intermediarios. El rivaroxaban es útil como inhibidor de la forma activa de coagulación X (factor Xa). Reivindicación 1: Un proceso en un solo recipiente para preparar Rivaroxaban, 5-cloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorfolin-4-il)fenil]oxazolidin-5-il]metil]tiofeno-2-carboxamida, de fórmula (1), o una forma estereoquímicamente isomérica o una mezcla racémica de las mismas, caracterizado porque comprende: a) hacer reaccionar ácido 5-clorotiofeno-2-carboxílico de fórmula (4) o una sal del mismo, con un agente sulfonilante de fórmula (5a) ó (5b) donde R es un grupo alquilo, cicloalquilo, haloalquilo, aralquilo, o arilo sustituido o no sustituido; para producir un compuesto éster de sulfonilo de fórmula (3), donde R es según se lo definió anteriormente; b) hacer reaccionar el compuesto éster de sulfonilo de fórmula (3) con la 4-[4-[(5S)-5-(aminometil)-2-oxo-1,3-oxazolidin-3-il]fenil]morfolina-3-ona de fórmula (2) o una forma estereoquímicamente isomérica o una mezcla racémica de las mismas, o una sal de adición ácida de las mismas, para producir el Rivaroxaban de fórmula (1) o una forma estereoquímicamente isomérica o una mezcla racémica de las mismas. Reivindicación 15: Un compuesto éster de sulfonilo de fórmula (3), caracterizado porque R es un grupo alquilo, cicloalquilo, haloalquilo, aralquilo, o arilo sustituido o no sustituido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2012/000321 WO2013164833A1 (en) | 2012-05-02 | 2012-05-02 | Improved process for preparing rivaroxaban using novel intermediates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090910A1 true AR090910A1 (es) | 2014-12-17 |
Family
ID=49514278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101486 AR090910A1 (es) | 2012-05-02 | 2013-05-02 | Proceso mejorado para preparar rivaroxaban utilizando intermediarios |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9376427B2 (es) |
| EP (1) | EP2844654B1 (es) |
| CN (1) | CN104487436B (es) |
| AR (1) | AR090910A1 (es) |
| AU (1) | AU2012378913B2 (es) |
| BR (1) | BR112014027248B1 (es) |
| CA (1) | CA2871339C (es) |
| CY (1) | CY1124179T1 (es) |
| ES (1) | ES2871811T3 (es) |
| IL (1) | IL235420A (es) |
| WO (1) | WO2013164833A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150218145A1 (en) * | 2012-09-26 | 2015-08-06 | Ranbaxy Laboratories Limited | Process for the preparation of rivaroxaban |
| CN103558326B (zh) * | 2013-11-12 | 2014-10-15 | 江苏正大清江制药有限公司 | 高效液相色谱法测定利伐沙班片中利伐沙班含量的方法 |
| IN2014MU00072A (es) | 2014-01-08 | 2015-08-21 | Wockhardt Ltd | |
| IN2014CH00290A (es) | 2014-01-23 | 2015-08-14 | Symed Labs Ltd | |
| CN107778303B (zh) * | 2016-08-27 | 2020-03-24 | 鲁南制药集团股份有限公司 | 利伐沙班的精制方法 |
| EP3565552B1 (en) | 2017-01-04 | 2022-05-11 | Unichem Laboratories Ltd | An improved process for the preparation of rivaroxaban involving novel intermediate |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE10300111A1 (de) | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
| DE102004002044A1 (de) | 2004-01-15 | 2005-08-04 | Bayer Healthcare Ag | Herstellverfahren |
| DE102007028406A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| ES2425183T3 (es) * | 2007-08-14 | 2013-10-11 | Concert Pharmaceuticals Inc. | Derivados de oxazolidinonas sustituidas |
| US8309547B2 (en) * | 2009-04-28 | 2012-11-13 | Apotex Pharmachem Inc. | Processes for the preparation of rivaroxaban and intermediates thereof |
| US7816355B1 (en) | 2009-04-28 | 2010-10-19 | Apotex Pharmachem Inc | Processes for the preparation of rivaroxaban and intermediates thereof |
| SI2459555T1 (sl) | 2009-07-31 | 2022-03-31 | Krka, D.D., Novo Mesto | Postopek kristalizacije rivaroksabana |
| EP2521723A1 (en) | 2010-01-04 | 2012-11-14 | Enantia, S.L. | Process for the preparation of rivaroxaban and intermediates thereof |
| EP2354128A1 (en) | 2010-02-10 | 2011-08-10 | Sandoz Ag | Method for the preparation of rivaroxaban |
| EP2388260A1 (de) | 2010-05-21 | 2011-11-23 | Archimica GmbH | Herstellungsverfahren für einen Inhibitor eines Blutgerinnungsfaktors |
| WO2012156983A1 (en) | 2011-05-16 | 2012-11-22 | Symed Labs Limited | Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide |
| CN102250077B (zh) * | 2011-06-15 | 2013-11-13 | 浙江工业大学 | 一种利伐沙班中间体及其用于合成利伐沙班的方法 |
-
2012
- 2012-05-02 CA CA2871339A patent/CA2871339C/en active Active
- 2012-05-02 AU AU2012378913A patent/AU2012378913B2/en not_active Ceased
- 2012-05-02 WO PCT/IN2012/000321 patent/WO2013164833A1/en active Application Filing
- 2012-05-02 EP EP12876006.3A patent/EP2844654B1/en active Active
- 2012-05-02 BR BR112014027248-4A patent/BR112014027248B1/pt not_active IP Right Cessation
- 2012-05-02 CN CN201280072871.3A patent/CN104487436B/zh not_active Expired - Fee Related
- 2012-05-02 US US14/397,551 patent/US9376427B2/en active Active
- 2012-05-02 ES ES12876006T patent/ES2871811T3/es active Active
-
2013
- 2013-05-02 AR ARP130101486 patent/AR090910A1/es active IP Right Grant
-
2014
- 2014-10-30 IL IL235420A patent/IL235420A/en active IP Right Grant
-
2021
- 2021-05-26 CY CY20211100456T patent/CY1124179T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013164833A1 (en) | 2013-11-07 |
| EP2844654A1 (en) | 2015-03-11 |
| US20150126733A1 (en) | 2015-05-07 |
| AU2012378913B2 (en) | 2017-04-13 |
| US9376427B2 (en) | 2016-06-28 |
| CY1124179T1 (el) | 2022-05-27 |
| ES2871811T3 (es) | 2021-11-02 |
| CA2871339C (en) | 2016-08-23 |
| EP2844654A4 (en) | 2017-12-06 |
| AU2012378913A1 (en) | 2014-11-13 |
| CN104487436B (zh) | 2017-05-24 |
| BR112014027248A2 (pt) | 2017-06-27 |
| IL235420A (en) | 2017-02-28 |
| BR112014027248B1 (pt) | 2021-01-26 |
| CN104487436A (zh) | 2015-04-01 |
| EP2844654B1 (en) | 2021-03-10 |
| CA2871339A1 (en) | 2013-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR090910A1 (es) | Proceso mejorado para preparar rivaroxaban utilizando intermediarios | |
| ATE545645T1 (de) | Neue cokristall-verbindung von rivaroxaban und malonsäure | |
| ES2395304B1 (es) | Procedimiento de obtención de una tiofen-2-carboxamida. | |
| EA201391647A1 (ru) | Способ получения ривароксабана и промежуточные соединения, получаемые в указанном способе | |
| PE20141322A1 (es) | Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina | |
| PE20130311A1 (es) | Composiciones y metodos para modular la via de senalizacion de wnt | |
| PE20091843A1 (es) | Inhibidores de catepsina c | |
| PE20091828A1 (es) | Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino como inhibidores de edg-2 | |
| PE20131153A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
| US20110034465A1 (en) | Processes for the preparation of rivaroxaban and intermediates thereof | |
| EP2630143B1 (en) | Processes for the preparation of rivaroxaban and intermediates thereof | |
| PE20141056A1 (es) | Metodos para el tratamiento de vhc | |
| PE20161396A1 (es) | Compuesto heterociclico | |
| PE20091002A1 (es) | Analogos dipeptidos como inhibidores del factor de coagulacion | |
| PE20160802A1 (es) | Inhibidores de dgat1 de eter ciclico de cabeza de puente | |
| AR076188A1 (es) | Derivados de oxadiazol | |
| PE20140188A1 (es) | Co-cristales y sales de inhibidores de ccr3 | |
| PE20181319A1 (es) | Compuestos de isoindol | |
| CY1109375T1 (el) | Παραγωγα αμινοακυλο-προφαρμακων και φαρμακα για τη θεραπεια θρομβοεμβολικων παθησεων | |
| PE20171620A1 (es) | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas | |
| CO6710902A2 (es) | Inhibidores de oxadiazol de la producción de leucotrienos | |
| AR088358A1 (es) | Proceso de obtencion de acidos isoxazolil-metoxi-nicotinicos | |
| PE20120537A1 (es) | Derivados de ciclopentano como inhibidores de catepsinas | |
| WO2012041263A3 (en) | A method of manufacturing 2-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]- l,3-oxazolidin-5-yl}methyl)-lh-isoindol-l,3(2h)-dione with a high optical purity | |
| PH12015501625A1 (en) | Aldehyde derivative of substitute oxazolidinones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |